Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Active immunization for the prevention of pneumococcal disease caused by the 23 serotypes Age: greater than 65 years |
Dose: Intramuscular Injection – 0.5 ml Frequency: Single dose Note: As 23-valent vaccine. Revaccination is not generally required except, after 5 years, in patients who may have rapidly declining antibody concentrations e.g. those with asplenia or splenic dysfunction, or those with nephrotic syndrome. |
|
Indication: Active immunization for the prevention of pneumococcal disease caused by the 23 serotypes Age: 2 years to 64 years Condition: High risk of pneumococcal disease (e.g., those with sickle cell disease, HIV infection, or other immunocompromising conditions) |
Dose: Intramuscular Injection – 0.5 ml Frequency: Single dose Note: As 23-valent vaccine. To be given at least 2 weeks before elective splenectomy, chemotherapy or other immunosuppressive treatment. Revaccination is not generally required except, after 5 years, in patients who may have rapidly declining antibody concentrations e.g. those with asplenia or splenic dysfunction, or those with nephrotic syndrome. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Active immunization for the prevention of pneumococcal disease caused by the 23 serotypes Age: Child greater than 2 years Condition: high risk of pneumococcal disease (e.g., those with sickle cell disease, HIV infection, or other immunocompromising conditions) |
Dose: Intramuscular Injection – 0.5 ml Note: As 23-valent vaccine: Single dose, to be given at least 2 weeks before elective splenectomy, chemotherapy or other immunosuppressive treatment. Revaccination is not generally required except, after 5 years, in patients who may have rapidly declining antibody concentrations e.g. those with asplenia or splenic dysfunction, or those with nephrotic syndrome. |
Administration
- Give in deltoid muscle or lateral thigh
- Use subcutaneous route if bleeding disorders
Side Effect
- Local Reactions at the Injection Site Pain
- erythema (redness)
- induration and oedema (swelling)
- These reactions are mild and transient
- Rare reactions eg Arthus phenomenon (severe local reactions) are reversible without after-effects
- they mainly occur in subjects with high initial levels of pneumococcal antibody
- Moderate and transient hyperthermia (fever) sometimes More than 39°C which generally occurs very shortly after vaccination and resolves within 24 hrs
- Other General Reactions Adenopathy (inflammation of the lymph nodes)
- rashes
- arthralgia (pain in the joints) and allergic reactions [urticaria
- Quincke'soedema (type of urticaria with sudden swelling of the face and neck)
- anaphylactoid reactions (severe allergic reaction)]
- headache
- muscle pain
- malaise
- and fatigue have exceptionally been reported
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Zostavax
|
Reduce immune response
|
|
Immunosuppressives
|
Interaction noted, but effect not specified
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Known allergy to components
|
Risk of severe allergic reaction
|
|
Acute disease or fever
|
Reduced vaccine effectiveness
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.